Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product

Core Viewpoint - Fractyl Health Inc. experienced a significant decline in stock price following a potential shift in its regulatory strategy for its lead product, Revita, which is designed to address chronic metabolic diseases [1][8]. Product Overview - Revita is a minimally invasive endoscopic procedure aimed at remodeling the duodenal lining to restore nutrient sensing and signaling disrupted by chronic metabolic disease [2]. - The product has received FDA Breakthrough Device designation for weight maintenance in patients who stop GLP-1 therapies [2]. Regulatory Strategy - The company is seeking FDA feedback on reclassifying Revita under the De Novo pathway instead of the Premarket Approval (PMA) process, which may allow for a more efficient regulatory review [3]. - Feedback from the FDA regarding the De Novo pathway is anticipated in the second quarter of 2026 [4]. Clinical Trial Results - In a six-month randomized study, Revita-treated patients showed a 4.5% weight regain compared to 7.5% in the sham group, indicating a significant reduction in expected weight regain after GLP-1 therapy discontinuation [5]. - An exploratory analysis indicated that patients with above-median weight loss during GLP-1 run-in experienced a 4.2% weight regain versus 13.3% in the sham group, reflecting a 70% relative reduction in post-GLP-1 weight regain [6]. Metabolic Improvements - Revita-treated patients exhibited improvements in cardiometabolic lipid parameters, including a 15.5 mg/dL increase in HDL cholesterol and a reduction in triglyceride-to-HDL ratio, suggesting enhanced metabolic regulation [7]. - Patient-reported outcomes indicated a significant reduction in sweet-food cravings in the Revita group compared to the sham group [7]. Safety Profile - The safety and tolerability of Revita remained favorable over six months, with no serious adverse events related to the device or procedure, and no study discontinuations due to adverse events [8].